Phase 1 Trial Lead, Senior Lecturer and Consultant Medical Oncologist, Cardiff University and Velindre Cancer Centre.
Rob is Speciality Lead for Cancer in Wales, Lead for Phase 1 trials in Wales, and Clinical Research Director at the Velindre NHS Trust. He comes from a research background having carried out a PhD in Cancer Research before studying Medicine in Oxford. Having completed Oncology training, he carried out a CRUK Clinician Scientist post before being appointed as Senior Lecturer in Medical Oncology in Cardiff. Since opening Wales’ first ‘First in Human’ trial approximately 8 years ago, Robert has led the development of the portfolio and has been Principal Investigator around 20 Phase 1 trials being delivered through the Velindre Cancer Research Trials Unit. He is also Chief Investigator on two other Investigator Led trials ‘FAKTION’ and ‘FURVA’, the former having reported Orally at ASCO 2019 and been published in Lancet Oncology in 2020. He also sits on the NCRI Strategy Advisory Group and is a member of the NCRI Colorectal and Early Phase Clinical Study Groups. Rob has also been a member CRUK Combinations Alliance Committee until April 2020.
Steve is the co-lead of the Early Phase Clinical Trials work package. He is an academic clinical haematologist and combines the role of Clinical Reader in the Institute of Cancer and Genetics at Cardiff University School of Medicine with clinical work as a Consultant Haematologist at the University Hospital of Wales where he serves as haematological cancer lead clinician.
Steve's clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, the myeloproliferative neoplasms and myelodysplastic syndromes. His chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies including 'back-to-bench' laboratory projects running alongside clinical trials. He serves as principal investigator for an evolving portfolio of early and later phase clinical studies.
Steve is extensively involved in the development of clinical research at a national level through activities within the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. His other roles include Cardiff lead for the Trials Acceleration Programme (now funded by Cure Leukaemia) and lead of Cardiff School of Medicine medical undergraduate haematology teaching.
Bob McAlister started his public involvement journey in 2015 when he was appointed to the newly formed Public Involvement Delivery Board which was established by Health and Care Research Wales to provide advice on the delivery and direction of involvement. Since that time he has gone on to become, amongst other things, a Public Research Partner at the WCRC and a member of the Advisory Board of the Wales School for Social Care Research. He was also the Welsh public Board member for the Development Partnership which devised the UK Standards for Public Involvement.
Until recently he undertook Attendance Support home visits for some Secondary Schools and prior to that he had a career in the Police Force. He resides in the Neath area.
Annmarie is the lead for our Personalised Patient Experience research and jointly initiated and developed the Centre’s Patient and Public Involvement model.
She is Marie Curie Professor of Supportive and Palliative Care and Scientific Director of the Marie Curie Palliative Care Research Centre.
She is Chair of the NCRI Advanced Disease and End of Life work stream, and is joint lead for the Palliative and Supportive Care work package for the HCRW PRIME centre.
Annmarie is interested in complex interventions and the patient experience at all levels, including the real time assessment of the impact of trial processes and interventions for issues of equipoise and effectiveness. Her primary research area is difficult areas of treatment decision-making in advanced cancer where the decision to treat with chemotherapy or radiotherapy becomes uncertain due to side effects in advanced disease. In the Personalised Patient Experience workstream she is developing methods to integrate the patient's priorities and preferences in decisions about treatment so that treatment decisions are framed around subjective outcomes, to supplement objective clinical data.
She is also interested in the acute and late effects of cancer treatments, including past cure. She has developed a portfolio of qualitative studies embedded within oncology and supportive care clinical trials and national and international multicentre qualitative studies. She has a strong interest in PPI and is joint lead (with Pro Matthias Eberle) for Engagement and PPI for the School of Medicine at Cardiff University.
Alan is a Reader in Translational Virotherapies based within the Division of Cancer and Genetics at Cardiff University School of Medicine. Alan has long standing experience in developing targeted, advanced therapeutics, gained from previous positions at the University of Birmingham (1998 – 2003), King’s College London (2003 – 2005) and the University of Glasgow (2005 – 2013).
His team study the adenovirus, using detailed information about how viruses interact with cells to develop targeted, bespoke virotherapies for a diverse array of cancer types. His team are supported by programmatic funding from Cancer Research UK, as well as funding from Cancer Research Wales, Tenovus Cancer Care and Knowledge Economy Skills Scholarship (KESS 2).
Amongst his varied other roles, Alan is a long standing, founding member of the British Society for Gene and Cell Therapy (BSGCT). He has been an elected board member since 2014 – the first (and only) BSGCT board member based in Wales, and in 2020 became treasurer for the society. In 2017 Alan established an active BSGCT subcommittee committed to the development of Early Career Researchers within the Gene and Cell Therapy field, which now runs as an annual networking and careers focussed meeting.
Originally from the South Wales valleys, Lee’s undergraduate training was completed in Cardiff University, followed by a PhD at the Institute of Medical Genetics at (what was then) the University of Wales College of Medicine. His Cancer Research Wales funded PhD was completed in the laboratory of Professors Julian Sampson and Jeremy Cheadle on the "Molecular and Functional Analysis of the Human Tumour Suppressor Genes TSC1 and TSC2". Upon completing his PhD in 2002 he took up a Postdoctoral Fellow position at the Murdoch Children's Research Institute (MCRI) within the Royal Children's Hospital in Melbourne, Australia. His work there was a change of focus from the cancer genetics of my PhD as he worked in the research groups of Prof Henrik Dahl and David Thorburn on Complex I deficiency in mitochondria. Upon completing this post, he returned to Cardiff University and to cancer genetics, working on a Cancer Research UK funded project in the laboratory of Prof Alan Clarke. In July 2013 he took up a fellowship at the European Cancer Stem Cell Research Institute where his research group focuses on the prevention and early detection of colorectal cancer. Prevention research focusses on understanding how the interactions between an individual’s diet, microbiome, metabolome, epigenome and immune system impacts on the intestinal stem cell to create an anti- or pro-tumourigenic environment. Early detection work focusses on the use of oncotrophic bacteria as a theranostic to identify and potentially treat solid tumours.
Sarah joined the Wales Cancer Research Centre as a Research Partner in October 2018. She was keen to get involved in this area of research as cancer has affected her both personally and through family experience.
Sarah has had skin cancers (basal cell carcinomas) removed from her neck and lower back, the most recent of which was diagnosed in early 2020. From a family perspective, her step-dad has been successfully treated for prostate cancer, but her auntie (her mum’s twin sister) was diagnosed with liver cancer which had spread to her lungs in November 2019, and she died a few weeks later. Unfortunately, Sarah has also lost other family members to various forms of cancer, one of whom lived with her throughout their illness and died at home.
Sarah has always had an interest in health and care research and so joined the public involvement community in May 2017. Since joining she has been afforded the opportunity to contribute to a number of studies. She is a member of the PRIME SUPER group, the Consumer Panel for Data Linkage Research, chair the National Centre for Population Health & Wellbeing Research (NCPHWR) PPI Group, and has been involved in planning Health & Care Research meetings/conferences. She also sits on several funding boards, providing public member input and perspective to funding decisions, and is a co-facilitator for the First Steps training course. As well as being Research Partner for our centre, she is a member of the Trial Management Groups (TMGs) for two cancer studies (PATHOS and ADVANCE) and the Cancer Research Strategy for Wales (CReST Cymru) writing group. She is also a Public Partner with Health Technology Wales, sitting on the Assessment Group and PPI Standing Group.
Dr Kathy Seddon is an elearning specialist. A Churchill Fellowship allowed her to set up an online collaboration between European schools she researched the success of their online collaboration in her Exeter University Doctorate "Teacher Motivation, Learning and Practice in an International Online community" She is an honorary Fellow of Exeter University. Kathy has a number of publications arising from her thesis and from her work with the National College for School Leadership in their online communities.
After the death of her husband from a glioblastoma she wanted to put her research skills to use as a ‘Research Voice’ for Marie Curie working on ‘missing data’ and 'Impact of research'. Kathy is a Research partner at the WCRC and has helped (PPI) with a number of completed projects. She has been a co-applicant on key pieces of research such as Bereavement, RAMBO, and PETROS. She has an interest in ethical approval, brain tumour research and in MDRG groups